Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)
Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, Steinseifer J, Ye C, Bardia A (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: AMER ASSOC CANCER RESEARCH
City/Town: PHILADELPHIA
Conference Proceedings Title: CANCER RESEARCH
DOI: 10.1158/1538-7445.sabcs20-ot-09-06
Authors with CRIS profile
Involved external institutions
F. Hoffmann-La Roche Ltd
Switzerland (CH)
Samsung Medical Center (SMC)
Korea, Republic of (KR)
Catalan Institute of Oncology / Institut Català d'Oncologia (ICO)
Spain (ES)
Genentech Inc.
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
Massachusetts General Hospital
United States (USA) (US)
Switzerland (CH)
Samsung Medical Center (SMC)
Korea, Republic of (KR)
Catalan Institute of Oncology / Institut Català d'Oncologia (ICO)
Spain (ES)
Genentech Inc.
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
Massachusetts General Hospital
United States (USA) (US)
How to cite
APA:
Hurvitz, S.A., Fasching, P., Park, Y.H., Quiroga, V., Crnjevic, T.B., Fresco, R.,... Bardia, A. (2021). Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC). In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MLA:
Hurvitz, Sara A., et al. "Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.
BibTeX: Download